Biomaterials for treatment and prevention of Alzheimer's disease
Tomás Sobrino, from SERGAS (Spain)
11 partners (Research Institutes, Universities, Companies, Hospitals)
Alzheimer’s disease (AD) is the leading cause of dementia and loss of autonomy in the elderly, involving a progressive cognitive decline and limitation of social activities. Progressive aging of EU population will increase the magnitude of this problem in next decades.
Currently, there is not an effective method for the early diagnosis of AD. Therefore, there is an urgent need to develop new effective early diagnostic and therapeutic strategies to help in delaying the appearance of the most adverse symptoms of this disease.
To defeat this challenge, PANA project bases its approach on the importance of researching in early pathophysiological processes of AD.
PANA project seeks that goal using nanotechnology. The proposal include an exclusive consortium which combines neuroscientists, nanotechnologists, molecular imaging experts, clinicians and Small/Medium/Large Enterprises in an effort to provide new very-early diagnostic tools for AD, a vital medical/social problem in EU.